AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,475.50GBp
2 Mar 2015
Change (% chg)

6.00p (+0.13%)
Prev Close
4,469.50p
Open
4,461.50p
Day's High
4,502.00p
Day's Low
4,461.50p
Volume
1,356,160
Avg. Vol
2,530,197
52-wk High
4,946.41p
52-wk Low
3,718.50p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.39
Market Cap(Mil.): £56,593.13
Shares Outstanding(Mil.): 1,263.22
Dividend: 125.00
Yield (%): 3.96

Financials

  AZN.L Industry Sector
P/E (TTM): 71.28 38.99 40.21
EPS (TTM): 0.63 -- --
ROI: 3.05 17.01 16.34
ROE: 5.75 17.53 17.27
Search Stocks

AstraZeneca to carve out antibiotic R&D into separate firm

LONDON - Drugmaker AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company, as it sharpens its focus on other therapy areas.

27 Feb 2015

UPDATE 1-AstraZeneca to carve out antibiotic R&D into separate firm

LONDON, Feb 27 - Drugmaker AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company, as it sharpens its focus on other therapy areas.

27 Feb 2015

AstraZeneca carving out antibiotic R&D into separate firm

LONDON, Feb 27 - Drugmaker AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company, as it sharpens its focus on other therapy areas.

27 Feb 2015

AstraZeneca taps biotech firm Orca for autoimmune disease drugs

LONDON - AstraZeneca has boosted its early-stage research in autoimmune disease by signing a three-year research deal with start-up firm Orca Pharmaceuticals, a small British biotech company formed in 2013, on a new class of drugs.

25 Feb 2015

AstraZeneca taps biotech firm Orca for autoimmune disease drugs

LONDON, Feb 25 - AstraZeneca has boosted its early-stage research in autoimmune disease by signing a three-year research deal with start-up firm Orca Pharmaceuticals, a small British biotech company formed in 2013, on a new class of drugs.

25 Feb 2015

AstraZeneca's patent on asthma drug invalidated by U.S. court

NEW YORK - A U.S. federal judge ruled late on Friday that AstraZeneca PLC's patent on its Pulmicort Repsules treatment for asthma was invalid, opening up the market to a second, cheaper generic version.

15 Feb 2015

AstraZeneca's patent on asthma drug invalidated by U.S. court

NEW YORK, Feb 15 - A U.S. federal judge ruled late on Friday that AstraZeneca PLC's patent on its Pulmicort Repsules treatment for asthma was invalid, opening up the market to a second, cheaper generic version.

15 Feb 2015

BRIEF-Almirall receives $150 million in milestones from Astrazeneca

* Says receives $150 million in milestones payments related to deal with Astrazeneca

13 Feb 2015

BRIEF-AstraZeneca to pay $7.9 million to resolve US kickback probe

Feb 11 - AstraZeneca PLC : * U.S. says Astrazeneca to pay $7.9 million to resolve kickback

11 Feb 2015

AstraZeneca to buy Actavis lung drugs as earnings fall short

LONDON - AstraZeneca said on Thursday it would buy Actavis' branded respiratory drug business in the United States and Canada for an initial $600 million as it reported disappointing fourth-quarter earnings. | Video

05 Feb 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks